Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091908 | 0.83 | L3MBTL1 (0.47) | ALDH1A1LMNAPOLBL3MBTL1TDP1 | |
| SCHEMBL27787105 | 0.82 | ALDH1A1 (0.53) | ALDH1A1NPSR1LMNAMAPTALK | |
| SCHEMBL3091958 | 0.82 | ALDH1A1 (0.48) | ALDH1A1NPSR1LMNAMAPTALK | |
| SCHEMBL3093669 | 0.80 | TGM2 (0.44) | ALDH1A1LMNAKDM4EPOLBMEN1 | |
| SCHEMBL3469893 | 0.79 | ALDH1A1 (0.48) | ALDH1A1NPSR1LMNAMAPTALK | |
| SCHEMBL15310228 | 0.76 | HSD17B10 (0.49) | ALDH1A1NPSR1LMNAMAPTKDM4E | |
| SCHEMBL3089049 | 0.75 | LMNA (0.50) | ALDH1A1LMNAMAPTKDM4EMAPK1 | |
| SCHEMBL3096925 | 0.74 | TSHR (0.41) | ALDH1A1NPSR1LMNAMAPTKDM4E | |
| SCHEMBL3092873 | 0.73 | HPGD (0.49) | ALDH1A1NPSR1LMNASMN1; SMN2POLB | |
| SCHEMBL3092696 | 0.73 | TRPM8 (0.44) | ALDH1A1NPSR1LMNAMAPTALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | ALDH1A1 617/4885NPSR1 879/4885LMNA 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.